The American Society for Radiation Oncology (ASTRO) has developed a model policy to provide guidance in the appropriate use of proton-beam therapy for cancer treatment. The list of criteria includes such factors as tissue toxicity and cumulative radiation exposure. ASTRO found evidence that proton therapy was warranted in a limited number of cancers, including ocular tumors, metastatic tumors of the spine, and patients with genetic syndromes that emphasize the importance of minimizing total radiation, among others.
Evidence to support reimbursement for proton-beam therapy remains limited to several relatively uncommon cancers, although some patients enrolled in clinical trials also should receive coverage consideration, according to the American Society for Radiation Oncology.
READ FULL ARTICLE
From Medical Page Today
Please login or register first to view this content.
Enjoying our content?
Thanks for visiting Oncology Nurse Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Please login or register first to view this content.
